Key model input parameters
| Parameters | Value | Range | Distribution | Resource |
| Drug cost (per cycle, US$) | ||||
| Rezvilutamide | 822.5 | 658–987 | Gamma | Local estimate |
| Bicalutamide | 120.67 | 96.54–144.80 | Gamma | Local estimate |
| Orchidectomy | 83.11 | 66.49–99.73 | Gamma | 19 |
| Leuprorelin | 181.67 | 145.34–218.00 | Gamma | Local estimate |
| Enzalutamide | 1082.67 | 866.14–1299.20 | Gamma | Local estimate |
| Abiraterone | 1687.16 | 1349.73–2024.59 | Gamma | Local estimate |
| Prednisone | 0.49 | 0.39–0.59 | Gamma | Local estimate |
| Disease management costs (per cycle, US$) | 390.02 | 312.02–468.02 | Gamma | Local estimate |
| AEs management cost (per cycle, US$) | 12.15 | 9.72–14.58 | Gamma | 19 |
| Health utilities | ||||
| PFS | 0.90 | 0.72–1.08 | Beta | 16 |
| PD | 0.77 | 0.61–0.92 | Beta | 16 |
| Discount rate | 5.00% | 0.00%–8.00% | – | 14 |
AEs, adverse events; PD, progressive disease; PFS, progression-free survival.